Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as modified mRNA encoding human, methylmalonyl-coenzyme A mutase
mRNA-3705 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| mRNA-3705 | EXPERIMENTAL | Participants will receive mRNA-3705 at the same dose levels at the same dosing interval (every 2 weeks \[Q2W\], or every 3 weeks \[Q3W\]) last received in the clinical study of mRNA-3705 in which they initially participated, unless the Sponsor recommends modification. |
| Name | Type | Description |
|---|---|---|
| mRNA-3705 | DRUG | A sterile liquid for injection |
Inclusion Criteria: * Completed the assigned dose regimen treatment time period in other clinical studies of mRNA-3705 or is eligible for early transition to this study because they missed more than 3 consecutive doses of study drug due to coronavirus disease 2019 (COVID-19) vaccination during Stud...
mRNA-3705 is an investigational RNA therapy developed by Moderna, Inc. for methylmalonic acidemia, a rare inherited metabolic disorder. It is in Phase 1 clinical development and is being studied in an extension trial evaluating long-term safety and clinical activity in participants previously enrolled in other mRNA-3705 studies.
mRNA-3705 is being developed as a treatment for methylmalonic acidemia, a rare disease in which the body cannot properly process certain amino acids and fats. It is investigational and has not been approved for any use. The ongoing Phase 1 extension study is evaluating its long-term safety and clinical activity.
mRNA-3705 is developed by Moderna, Inc., which trades on the Nasdaq under the ticker MRNA. Moderna is the sponsor of the clinical program studying the therapy in methylmalonic acidemia.
mRNA-3705 is in Phase 1 clinical development. It is an investigational therapy and is not approved by the FDA. The program consists of one active, recruiting Phase 1 extension study with a planned enrollment of 56 participants.
mRNA-3705 is being studied in the Phase 1 extension trial NCT05295433, titled an extension study to evaluate the long-term safety and clinical activity of mRNA-3705 in participants previously enrolled in other clinical studies of mRNA-3705. The trial is recruiting in the United States, Canada, France, Netherlands, Spain, and the United Kingdom.